

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT

PRE-NDA MEETING APPLICATION FOR QUADRA-VALENT MENINGOCOCCAL CONJUGATE VACCINE

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that, according to Measures for Administration of Communication of Drug Development and Technical Review (藥物研發與技術審評溝通交流管理辦法), the Company has completed the application package for the new drug application (the “**NDA**”) for the Company’s groups A, C, Y and W135 meningococcal conjugate vaccine (“**MCV4**”) (the “**Filing**”), and submitted for the pre-NDA meeting to the National Medical Products Administration (“**NMPA**”) on July 5, 2019. The Company will make the Filing as soon as practicable based on NMPA’s response.

The Filing is potentially the first NDA for MCV4 in China, and the Company’s MCV4 candidate is a potential China first-in-class vaccine preventing meningitis which was found to be safe and well-tolerated, and showed good immunogenicity in age groups from 3 months to 6 years old. It is designed to be comparable to vaccines manufactured by multinational companies which are widely used in developed countries.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to develop, or ultimately market, MCV4 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

For and on behalf of
CanSino Biologics Inc.
Xuefeng YU

Chairman and chief executive officer

Hong Kong, July 8, 2019

As at the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive Directors.